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AbstrACt
Objective Complicated urinary tract infections (cUTIs) 
impose a high burden on healthcare systems and are 
a frequent cause of hospitalisation. The aims of this 
paper are to estimate the cost per episode of patients 
hospitalised due to cUTI and to explore the factors 
associated with cUTI-related healthcare costs in eight 
countries with high prevalence of multidrug resistance 
(MDR).
Design This is a multinational observational, retrospective 
study. The mean cost per episode was computed by 
multiplying the volume of healthcare use for each patient 
by the unit cost of each item of care and summing across 
all components. Costs were measured from the hospital 
perspective. Patient-level regression analyses were used 
to identify the factors explaining variation in cUTI-related 
costs.
setting The study was conducted in 20 hospitals in eight 
countries with high prevalence of multidrug resistant 
Gram-negative bacteria (Bulgaria, Greece, Hungary, Israel, 
Italy, Romania, Spain and Turkey).
Participants Data were obtained from 644 episodes of 
patients hospitalised due to cUTI.
results The mean cost per case was €5700, with 
considerable variation between countries (largest value 
€7740 in Turkey; lowest value €4028 in Israel), mainly 
due to differences in length of hospital stay. Factors 
associated with higher costs per patient were: type of 
admission, infection source, infection severity, the Charlson 
comorbidity index and presence of MDR.
Conclusions The mean cost per hospitalised case of cUTI 
was substantial and varied significantly between countries. 
A better knowledge of the reasons for variations in length 
of stays could facilitate a better standardised quality of 
care for patients with cUTI and allow a more efficient 
allocation of healthcare resources. Urgent admissions, 
infections due to an indwelling urinary catheterisation, 
resulting in septic shock or severe sepsis, in patients with 
comorbidities and presenting MDR were related to a higher 
cost.
IntrODuCtIOn  
Urinary tract infections (UTIs) are highly 
prevalent worldwide. UTIs that occur in a 
strengths and limitations of this study
 ► This is the first study to examine costs of hospital-
ised patients due to complicated urinary tract infec-
tion (cUTI) from a multinational point of view.
 ► It is focused on countries with a high prevalence of 
multidrug resistance bacteria where cUTI impose a 
significant burden.
 ► The study estimates the mean cost per case from a 
bottom-up perspective, which provided a high level 
of granularity and the basis for the assessment of 
sources of variation and drivers of healthcare costs.
 ► The design of the study did not include a control 
group to assess the extra length of stay and excess 
costs of patients who are admitted to hospital due to 
a different condition and develop urinary tract infec-
tion during their hospitalisation.
 ► Country-specific unit cost data were not appropriate 
for most countries, and therefore, we applied the 
same set of unit costs, as estimated in one country, 
Spain, to the rest of the countries.
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normal genitourinary tract with no prior instrumenta-
tion are considered uncomplicated, whereas complicated 
UTIs (cUTIs) are associated with structural or functional 
abnormalities of the genitourinary tract or an underlying 
disease that interferes with host defence.1 cUTIs are a 
frequent cause of hospitalisation as well as a common 
complication during hospitalisation and have shown a 
higher prevalence of antimicrobial resistance compared 
with uncomplicated UTI.2 Due to the rapid emergence 
and dissemination of resistance to antimicrobial agents, 
leading in some cases to multidrug resistance (MDR), 
some patients with cUTI are left with few therapeutic 
options and may progress to more serious stages of the 
disease.3 
Currently, information about the burden of cUTI is 
scarce. Reports from the USA show that in the year 2000 
cUTI accounted for more than 100 000 hospital admis-
sions, often as a result of pyelonephritis.4 Data from 
Europe are very limited, although the last point preva-
lence survey of European acute care hospitals estimated 
the prevalence of healthcare-associated infections to be 
6%; of these, UTI was the third most common infection 
(19%).5 Based on these point prevalence data, the annual 
health burden of hospitalised patients with UTI was esti-
mated to be 81.2 disability-adjusted life years per 100 000 
individuals in the general population.6
Despite this high burden to healthcare systems and 
the increased pressure for cost containment in health-
care, few studies have examined the costs of cUTIs. Some 
papers have measured the cost of community-acquired 
UTIs7–10 and nosocomial UTIs,11 12 or both.13 Most of these 
studies were conducted in the USA,7 8 11–13 while studies 
undertaken in European countries have mainly focused 
on women visiting primary care settings with suspected 
UTIs.9 10 Some papers have estimated the impact of 
extended-spectrum beta-lactamase (ESBL)-producing 
Escherichia coli on the cost of UTI episodes requiring hospi-
talisation.14 15 Estimating the magnitude of the financial 
impact of this prevalent and potentially avoidable condi-
tion is particularly useful for measuring the potential 
cost savings from averting a case, thereby emphasising 
the importance of prevention and the sizeable economic 
consequences of MDR. In addition, cost estimates might 
inform cost-effectiveness analyses that require data on 
episode costs in order to compare alternative courses of 
treatment related to this condition. Therefore, there is a 
need for data on the economic burden imposed to health-
care systems due to hospitalised cUTI patients, especially 
in countries with high prevalence of MDR.
In this paper, we present an analysis of the economic 
burden of cUTI in seven European countries plus Israel, 
all of which have a high prevalence of MDR. The aims of 
this study are to estimate the cost per case of hospitalised 
patients due to cUTI and to investigate the factors associ-
ated with cUTI-related healthcare costs.
The analyses reported in this paper are part of a larger 
project, ‘REtrospective observational Study to assess 
the clinical management and outcomes of hospitalised 
patients with Complicated Urinary tract INfection in 
countries with high prevalence of multidrug resistant 
Gram-negative bacteria (RESCUING study)’, with an 
overall aim of providing information about the epide-
miology, clinical management, outcomes and healthcare 
costs of patients hospitalised with cUTI.
MAterIAls AnD MethODs
setting
This is a multinational observational, retrospective study 
conducted in 20 hospitals in eight countries (Bulgaria, 
Greece, Hungary, Israel, Italy, Romania, Spain and Turkey). 
Data were collected on patients who had a diagnosis of cUTI 
as the primary cause of hospitalisation and patients hospi-
talised for another reason but who developed cUTI during 
their hospitalisation from January 2013 to December 2014, 
based on International Classification of Diseases, 9th Revi-
sion (ICD-9) and ICD, 10th Revision (ICD-10) codes (ICD-9 
Clinical Modification (CM) codes: 590.1, 590.10, 590.11, 
590.2, 590.8, 590.80, 590.9, 595.0, 595.89, 595.9 and 599.0; 
ICD-10 CM codes: N10, N12, N13.6, N15.1, N15.9, N30.0, 
N30.8, N30.9 and N39.0). The study protocol has been 
published elsewhere.16
In order to avoid selection bias, all consecutive patients 
who had ICD-9 or ICD-10 CM codes were reviewed at 
each site. All patients who met the inclusion criteria were 
selected for data collection. Inclusion criteria were patients 
with UTI and at least one of the following: indwelling 
urinary catheter, urinary retention, neurogenic bladder, 
obstructive uropathy, renal impairment caused by intrinsic 
renal disease, renal transplantation, urinary tract modifi-
cations, pyelonephritis and normal urinary tract anatomy, 
and at least one of the following signs or symptoms: chills 
or rigours associated with fever or hypothermia, flank pain 
(pyelonephritis) or pelvic pain (cUTI), dysuria or urinary 
frequency, or urinary urgency, costovertebral angle tender-
ness on physical examination and either urine culture with 
at least 105 CFU/mL or greater of a uropathogen (no more 
than two species) or at least one blood culture growing 
possible uropathogens (no more than two species) with no 
other evident site of infection. These inclusion criteria are 
in accordance to the definition of cUTI provided in ref 17. 
The analysis presented in this paper focuses on patients 
admitted to hospital because of cUTI only; we do not 
include patients admitted for other reasons who developed 
cUTI during hospitalisation. The reason is that in the case 
of latter it is not possible to isolate the incremental cost of 
cUTI without a matched control group, that is, comparing 
similar patients with and without cUTI during their hospital 
stay (see, eg, ref 18). Our data indicate that the proportion 
of cUTI that are the cause of hospital admission is 65% 
versus a 35% that develop cUTI during hospitalisation.
study data collection
Data were collected retrospectively for all cUTI episodes 
at participating hospitals during the study period. For all 
patients, a standardised set of information was recorded. 
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This consisted of demographics, comorbidities including 
those required to calculate a modified Charlson score,19 
place of acquisition of infection, infection source and 
severity, microbiological data, imaging test data, infec-
tion management, antibiotic therapy, outcomes, details 
of discharge and readmissions. The follow-up period was 
2 months after discharge from the admitting hospital.
The perspective of the cost analysis was the hospital 
provider, as we focus on hospitalised patients with cUTI, 
and this is where the majority of the cost burden falls.20 21
Study size was defined based on the primary outcome 
measure of the main study, that is. treatment failure rate 
between MDR bacteria and other pathogens.16
estimating the cost per case of cutI
We collected information on healthcare resource utili-
sation attributed to cUTI for each episode in the dataset. 
The healthcare components collected were: (1) length of 
hospital stay (LOS) (general ward and intensive care unit 
(ICU)), (2) diagnostic and follow-up tests, (3) urolog-
ical interventions and haemodialysis, (4) antibiotic treat-
ment before, during and after hospitalisation and (5) 
hospital readmissions and outpatient visits within 60 days 
of discharge. For each component, a comprehensive list 
of specific items was compiled and reviewed by a clinical 
expert so that it included only healthcare resources that 
could be attributed to cUTI.
For unit costs, we planned to use the tool developed by 
WHO-CHOICE health service delivery costs,22 which provides 
information on the unit costs of bed-days and outpatient 
visits across 191 countries. Unfortunately, unit costs from 
this tool are only available for inpatient and outpatient visits, 
and for 2007–2008, and therefore they could not be used 
in our study. Instead, unit cost data for each cost item were 
collected for each country by means of a questionnaire sent 
to the principal investigators of all participating sites. The 
questionnaire was provided as an online and paper version 
and included the list of all healthcare services identified for 
the management of cUTI (see supplementary material 1). 
The response rate for the questionnaire was 90% (18 out of 
20). We received at least one response from each country. 
However, despite efforts to facilitate the complete fulfilment 
and harmonisation of the questionnaires, responses from 
some of the sites had missing values for key healthcare costs 
items, such as the cost of a day in hospital and for the most 
frequent diagnostic tests and treatment procedures. Further-
more, some sites provided the data in terms of user charges 
instead of the cost incurred by the hospital in the provision 
of the services. As a result, we observed a large degree of vari-
ation in unit costs across sites that was not attributable only 
to differences in actual costs between regions. Therefore, we 
generated a single set of unit costs based on the mean values 
across three sites within the same country, Spain, which 
provided consistently estimated values reflecting hospital 
costs for all the items included in the questionnaire. Using 
a common set of unit costs across all patients means that any 
observed variation in costs is due to differences in healthcare 
resource use. We discuss the limitations of this approach in 
the discussion section.
For antibiotic therapy, we estimated the cost per mg 
for each drug for which unit cost data were available 
and applied the mean cost per mg to the remaining 
therapies. We estimated the cost per day with antibiotic 
therapy based on the dosage and frequency recorded 
for each drug, which was then combined with the dura-
tion of the treatment to estimate total antibiotic therapy 
costs. Patients might receive more than one antibiotic 
drug at the same time; in that case, they count as sepa-
rate antibiotic therapy days. Patients with total hospital 
LOS >200 days were excluded (three observations) as 
these were deemed to be due to coding errors.
We computed means and SD as well as medians and 
IQRs for the cost per case, and we quantified the contri-
bution of each cost item and overall healthcare compo-
nent to the total cost per case. We also present variations 
in the overall cost per case by country and for different 
cost components. All costs were reported in 2016 euros.
Costs were calculated for each case of cUTI requiring 
a hospital admission. If a patient required a second 
hospital admission, then if this occurred within 60 days of 
discharge of the first admission, it was counted as a read-
mission and included in the cost of the first admission. If 
another admission occurred after 60 days postdischarge 
(either of the index admission or a readmission), then 
this was counted as a separate case (observation) in the 
data.
Factors associated with cutI-related healthcare costs
The analysis of the factors associated with cUTI-related 
healthcare costs was undertaken using multivariate regres-
sion analysis using patient level cost data. The dependent 
variable was total cost per patient estimated as described 
above.
The explanatory variables were demographic factors 
(age and gender), comorbidities measured by the Charlson 
morbidity index,18 admission characteristics (urgent 
vs elective; and admitted from home vs from another 
facility), infection severity (defined as septic shock or 
severe sepsis), MDR profile (defined as non-susceptibility 
to at least one agent in three or more antimicrobial cate-
gories23), episode number and 30-day mortality. We catego-
rised the source of infection using the following definitions: 
(1) UTI related to indwelling urinary catheterisation 
including long-term, short-term or intermittent catheter-
isation; (2) pyelonephritis, consisting of inflammation of 
the kidney tissue caused by bacterial infection in patients 
that have no other urinary tract modification; and (3) other 
sources, which includes UTI related to anatomical urinary 
tract modification, UTI related to obstructive uropathy 
and UTI related to other events that do not fulfil any other 
category. We ran three sets of models: (1) univariate regres-
sion models for each variable separately, (2) a multivariate 
model including all the covariates and (3) a reduced multi-
variate model including only significant variables (where in 
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the case of categorical variables, at least one indicator was 
non-significant).
Analyses were undertaken using Stata V.12. More 
details about the statistical methods used in the analyses 
are reported in the online supplementary material 2.
results
study population characteristics
Data were collected on 653 cUTI episodes in 637 patients 
(mean number of episodes per patient: 1.04). There were 
missing data on LOS for nine episodes, so mean costs per 
case were computed for 644 cases. Most common causative 
pathogens in this sample were E. coli (58%), Klebsiella sp. 
(14%), Proteus mirabilis (7%), Pseudomonas aeruginosa (6%) 
and Enterococcus sp. (5%). This is consistent with previous 
studies that have found E. coli to be the most commonly 
isolated organism, especially in cUTI acquired at the 
community,24 which were the majority in our sample (69% 
vs 31% associated to healthcare facilities).
Fifty-seven per cent of the cohort were females, and the 
mean age was 65.7 years (table 1). Mean Charlson comor-
bidity score was 2.4. Ninety-one per cent of admissions were 
urgent (as opposed to elective), and 85% of the patients 
were admitted from home (as opposed from another 
facility). The infection source was indwelling urinary cath-
eterisation in 20% of cases, pyelonephritis in 27% of cases 
and other sources (including anatomical urinary tract 
modification and obstructive uropathy) in the remaining 
53%. Twenty-six per cent of the episodes were caused by 
MDR bacteria. The severity of the infection was categorised 
as severe sepsis or septic shock in 16% of cases. Five per cent 
of the sample died within 30 days of discharge. The propor-
tion of cases collected by each country ranged from 5% in 
Bulgaria to 26% in Israel.
estimating the cost per case of cutI
Table 2 presents unit costs, resource use and total costs 
separately for each healthcare item as well as for each set 
of overall cost components. The mean (median) length of 
Table 1 Summary statistics of cohort characteristics and regression analysis results of total cost per cUTI episode
N (%)
Univariate analysis‡ (95% CI)
Multivariate analysis Multivariate analysis
Mean (SD)† Full model§ (95% CI) Reduced model¶(95% CI) 
Demographics
  Age 65.7 (18.66)† 19.77 (−7.5 to 47) 11.76 (−3.5 to 27) 
  Female 371 (58) −796.06 (−1872.5 to 280.4) 17.59 (−582.8 to 618) 
Type of admission
  Urgent (vs elective) 585 (91) 458.91 (−775.4 to 1693.2) 937.87** (44.8 to 1830.9) 991.32** (84.6 to 1898) 
  From home (vs other facility) 549 (85) −677.89 (−2429.6 to 1073.8) −577.62 (−1672.4 to 517.1) 
Infection source (vs catheterisation)
  Pyelonephritis 171 (27) −1673.18*** (−2819.3 to −527) −1802.63*** (−2812.8 to − 792.4) −1891.57*** (−2864.4 to −918.7)
  Other source 344 (53) −821.88 (−1946.1 to 302.3) −709.83 (−1672.3 to 252.6) −760.95* (−1690.3 to 168.4) 
Infection severity (vs other)
  Septic shock/severe sepsis 100 (16) 2415.49*** (1050.8 to 3780.2) 1671.77*** (437.9 to 2905.6) 1587.57** (280.7 to 2894.5) 
Charlson comorbidity index 2.4 (2.39)† 324.34*** (116.8 to 531.9) 230.85** (28.1 to 433.6) 263.48*** (53.9 to 473.1)
Episode number 1.04 (0.24)† 1394.33*** (363.8 to 2424.8) 355.91 (−522 to 1233.9) 
Mortality 30 days (yes vs no) 29 (5) 571.66 (−2511.2 to 3654.5) −934.75 (−3510.7 to 1641.2) 
Multidrug resistant (yes vs no) 166 (26) 626.99 (−421.5 to 1675.5) 475.92 (−221.6 to 1173.4) 581.41* (−98 to 1260.8)
Country (vs Turkey)
  Greece 65 (10) −597.99 (−2692.5 to 1496.5) −1503.81 (−3933.1 to 925.5) −1263.11 (−3782.8 to 1256.6)
  Hungary 49 (8) −1734.5** (−3216.4 to −252.6) −2757.06*** (−4101.8 to −1412.3) −2768.68*** (−4278.8 to −1258.5) 
  Israel 170 (26) −3612.37*** (−4659.1 to −2565.7) −4242.55*** (−5395.7 to −3089.4) −4007.09***(−5426.5 to −2587.7) 
  Italy 36 (6) −319.91 (−1648.8 to 1008.9) −1065.03* (−2358.1 to 228) −930.92 (−2501 to 639.2)
  Romania 107 (17) −2389.75*** (−3438.9 to −1340.6) −2024.15*** (−3149.8 to −898.5) −1931.49*** (−3301.5 to −561.5) 
  Spain 126 (20) −819.22 (−1942.5 to 304.1) −1629.41*** (−2756.9 to −501.9) −1422.96** (−2812.8 to −33.1)
  Bulgaria 31 (5) −2520.07*** (−4454.5 to −585.6) −2853.38*** (−4068.1 to −1638.7) −2841.09*** (−4354.9 to −1327.2)
  Pseudo-R2 N/A N/A 0.111 0.105
Sample size‡ 644 636†† 
*P<0.1. **P<0.05. ***P<0.01.
†Summary statistics for continuous variables are shown as mean and SDs; for categorical variables we present total number of observations and percentage.
‡Marginal effects of univariate regression models for each variable separately.
§Marginal effects of a multivariate model including all the covariates.
¶Marginal effect of a reduced multivariate model including only significant variables.
††There are eight cases with missing data on mortality at 30 days. Therefore, the sample used in the regression analyses includes 636 cases out of the 644 cases 
for whom data on cost per case was available.
cUTI, complicated urinary tract infection; N/A, not applicable.
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stay in hospital was 9 (7) days, and a small proportion of the 
total stay was in the ICU. Most patients had urine cultures, 
urinary sediment analyses and blood cultures undertaken, 
while imaging tests were rarely performed. The urological 
intervention most often performed was the insertion of an 
indwelling bladder-catheter. The mean number of antibi-
otic therapy days before, during and after hospitalisation 
were 2, 12 and 6 days, respectively. Nearly 10% of patients 
Table 2 Cost per case by cost component—all countries combined
Unit cost 
(€)
Resource use (units) Total cost (€)
%Mean (SD) Median [Q1–Q3] Mean (SD) Median [Q1–Q3]
Length of stay
  General ward (days) 477.4 9.25 (8.49) 7 [5–11] 4418.5 (4052.4) 3342 [2387–5252] 77.4
  ICU (days) 1589.6 0.05 (1.19) 0 [0–0] 83.9 (1895.4) 0 [0–0] 1.5
9.30 (8.51) 7 [5–11] 4502.4 (4389.9) 3342 [2387–5252] 78.9
Diagnostic tests
  Urine culture test 15.1 1.51 (0.82) 1[1–2] 22.8 (12.5) 15 [15–30] 0.4
  Dipstick analysis 2.8 0.49 (0.85) 0 [0–1] 1.3 (2.3) 0 [0–3] 0.0
  Urinary sediment analysis 2.6 1.02 (0.89) 1 [0–1] 2.6 (2.3) 3 [0–3] 0.0
  Gram stain test 6.3 0.37 (0.68) 0 [0–1] 2.3 (4.2) 0 [0–6] 0.0
  Blood culture 36.7 1.43 (1.56) 1 [0–2] 52.5 (57.1) 37 [0–73] 0.9
  Abdominal ultrasonography 48.9 0.71 (0.64) 1 [0–1] 34.5 (31.3) 49 [0–49] 0.6
  CT scan 156.0 0.2 (0.46) 0 [0–0] 32 (72.5) 0 [0–0] 0.6
  Pyelography 105.1 0.02 (0.14) 0 [0–0] 2 (14.2) 0 [0–0] 0.0
  MRI scan 191.6 0 (0.07) 0 [0–0] 0.9 (13.1) 0 [0–0] 0.0
151 (109) 115 [75–201] 2.6
Treatment procedures
  Insertion of catheter 50.0 0.36 (0.48) 0 [0–1] 17.8 (24) 0 [0–50] 0.3
  Replacement of catheter 50.0 0.13 (0.38) 0 [0–0] 6.5 (19) 0 [0–0] 0.1
  Percutaneous nephrostomy 717.6 0.05 (0.26) 0 [0–0] 37.9 (183.8) 0 [0–0] 0.7
  Insertion of JJ-stent 907.0 0.05 (0.21) 0 [0–0] 40.8 (188.2) 0 [0–0] 0.7
  Abscess drainage 557.6 0.01 (0.12) 0 [0–0] 6.9 (69.2) 0 [0–0] 0.1
  Nephrectomy 3174.0 0.01 (0.08) 0 [0–0] 19.7 (249.6) 0 [0–0] 0.3
  Mechanical ventilation (days) 350.0 0.12 (0.99) 0 [0–0] 41.8 (346.4) 0 [0–0] 0.7
  Renal replacement (days) 254.7 0.16 (1.53) 0 [0–0] 41.9 (389.8) 0 [0–0] 0.7
213.4 (764.8) 0 [0–50] 3.7
Antibiotic therapy
  Before hospitalisation (days) 1.9 1.95 (5.84) 0 [0–0] 2.6 (20.6) 0 [0–0] 0.0
  During hospitalisation (days) 12.3 12.25 (61.37) 7 [4–11] 197.8 (474.8) 19 [7–149] 3.5
  At discharge (days) 5.9 6 (13.61) 4.5 [0–8] 24.1 (117.5) 2 [0–10] 0.4
1.08 (4.53) 0 [0–0] 224.6 (490.3) 32 [14–199] 3.9
After discharge
  Readmission (days) 477.4 1.08 (4.53) 0 [0–0] 515.2 (2163.4) 0 [0–0] 9.0
  Outpatients (visits) 122.3 0.81 (1.62) 0 [0–1] 99.2 (197.8) 0 [0–122] 1.7
614.4 (2197.5) 0 [0–245] 10.8
Total (first hospital admission only) 5064 (4847) 3627 [2531–5985] 88.8
Total (first hospital admission+antibiotic treatment before and after discharge) 5091 (4844) 3651 [2542–6004] 89.2
Total (hospital admission+antibiotic treatment before and after 
discharge+readmissions and outpatients visits)
5705 (5438) 3919 [2664–6655] 100
*Unit costs estimated from the three Spanish sites.
ICU, intensive care unit.
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were readmitted to hospital due to a cUTI recurrence, with 
a mean readmission stay across the full sample of 1 day 
(11 days among the subsample of readmitted patients). The 
mean number of outpatient visits per patient within 60 days 
of hospital discharge was 0.8.
The mean (median) costs per case were: (1) including 
costs incurred during the first hospital admission: €5064 
(€3627); (2) plus antibiotic therapy before and after 
discharge: €5091 (€3651); and (3) plus outpatient visits 
and hospital readmissions within 60 days of discharge: 
€5705 (€3919).
The cost per case was largely driven by the cost due to 
the length of stay in hospital, which accounted for nearly 
80% of the total cost. This was followed by the contribu-
tion of the cost of readmissions and outpatient visits after 
discharge (11%), treatment procedures (4%), antibiotic 
therapy (4%) and diagnostic tests (3%).
There was variation in the mean cost per cUTI case 
by country, with a largest mean (median) value of 
€7740 (€5962) in Turkey and a lowest value of €4028 
(€3159) in Israel (table 3). Note that variations in total 
costs shown in this table are only due to variations in the 
management of patients with cUTI, including LOS, as 
unit costs of healthcare services are held constant across 
all countries. Table 3 also shows variations by cost compo-
nents between countries. This suggests that differences 
in LOS are the main reason of the observed differences 
in total costs between countries; the mean stay in hospital 
in a general ward varies from 6 days in Israel to 14 days 
in Italy.
Factors associated with cutI-related healthcare costs
The statistically significant drivers of cUTI-related health-
care costs were (table 1): type of admission (with urgent 
admissions exhibiting a higher cost than elective admis-
sions); source of infection (with catheterisation associated 
to higher costs compared with other sources); the infec-
tion severity (septic shock and severe sepsis showing a 
larger cost); the Charlson comorbidity index (with larger 
values associated to a higher cost); MDR profile (episodes 
presenting MDR showing a higher cost; only significant at 
10% significance level); and country (with most countries 
exhibiting a significant lower cost than Turkey).
DIsCussIOn
In this study we have measured the cost per episode of 
patients hospitalised due to cUTI in eight countries with 
high prevalence of MDR and explored the factors that 
explained variations in cUTI-related healthcare costs. 
The mean cost per hospitalised cUTI case in our data 
was estimated as €5700, corresponding to the costs of a 
hospital stay of 9 days on average and including the costs 
of specific diagnostic and treatment procedures, as well 
as antibiotic therapy, readmissions due to cUTI reoccur-
rence and outpatient visits after discharge. As expected, 
the largest cost component was LOS, but it is also worth 
noting that the cost of antibiotic treatment exceeded 
that incurred to perform diagnostics tests, and it was 
also larger than the costs due to any other treatment 
received by these patients. The cost per case varied across 
Table 3 Mean cost per case by cost component—by country





Bulgaria 31 Mean (SD) 4907 (4130) 3943 111 298 355 200 8.26 0.00
Median [Q1–Q3] 3660 [3187–5258] 2865 84 0 25 245 6.00 0.00
Greece 65 Mean (SD) 7039 (5786) 5670 221 251 586 311 11.88 0.00
Median [Q1–Q3] 5581 [3176–8934] 4774 213 50 70 122 10.00 0.00
Hungary 49 Mean (SD) 5656 (5591) 4044 170 519 35 888 8.47 0.00
Median [Q1–Q3] 3765 [2606–5905] 2865 137 0 19 122 6.00 0.00
Israel 170 Mean (SD) 4028 (2843) 3061 133 60 132 641 6.41 0.00
Median [Q1–Q3] 3159 [2254–4666] 2387 110 50 16 0 5.00 0.00
Italy 36 Mean (SD) 7221 (8271) 6525 173 38 431 54 13.67 0.00
Median [Q1–Q3] 5052 [3670–7735] 4536 145 0 268 0 9.50 0.00
Romania 107 Mean (SD) 5024 (3636) 4493 107 10 125 288 9.41 0.00
Median [Q1–Q3] 4314 [3096–5849] 3819 97 0 37 0 8.00 0.00
Spain 126 Mean (SD) 6674 (6200) 4706 193 342 153 1281 9.86 0.00
Median [Q1–Q3] 3992 [2705–8696] 3103 141 0 45 122 6.50 0.00
Turkey 60 Mean (SD) 7740 (8006) 6359 105 512 387 376 11.43 0.57
Median [Q1–Q3] 5962 [3375–9061] 4774 106 50 101 0 9.00 0.00
*Holding unit costs constant.
ATB, antibiotic therapy; DIAG, diagnostic test; DISCH, after discharge (readmission and outpatient visits); ICU, intensive care unit; LOS, length 
of stay; TREAT, treatment procedures. 
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countries, mainly due to differences in LOS in hospital 
among patients with cUTI. These differences in LOS do 
not appear to be related to the models of healthcare in 
each participating country—the countries with longest 
LOS, Turkey, Italy and Greece, have different healthcare 
systems, that is, social insurance system, national health 
system and mixed system, respectively. Several factors 
might explain these cross-country variations, including 
financial incentives inherent in hospital payments 
methods, availability of beds and the expansion of early 
discharge programmes that allow patients to return to 
their homes to receive follow-up care.25
Over and above differences across countries, our 
analysis also identifies a series of factors associated with 
higher cUTI-related healthcare costs. Urgent admissions, 
for infections due to an indwelling urinary catheterisa-
tion, resulting in septic shock or severe sepsis, in patients 
with a higher comorbidity index and presenting MDR 
were related to a higher cost. The presence of catheter 
on admission and the Charlson comorbidity index have 
also been found in the literature to increase costs of 
adult patients hospitalised with UTI, together with time 
to appropriate therapy.13 Another study found males, 
patients with chronic renal failure, ESBL production 
and outpatient parenteral antibiotic therapy to be asso-
ciated with higher costs in patients with UTI admitted to 
hospital.15
Our cost estimates are in line with previous studies that 
have focused on similar patient groups. Esteve-Palau et 
al15 estimated a mean cost per patient hospitalised with 
symptomatic UTI caused by ESBL-producing E. coli of 
€4980 in one hospital in Spain, excluding readmissions. 
The cost was significantly lower, €2612, among patients 
with UTI due to non ESBL-producing E. coli. Cardwell 
et al13 analysed data on adults patients with a discharged 
diagnosis code for UTI in one hospital in the USA 
and found a mean hospitalisation cost of $7586. The 
costs of nosocomial UTI infections and UTI infections 
seen in primary care have been shown to be lower. For 
instance, Saint12 estimated the incremental cost of noso-
comial UTIs of $676 and catheter-related bacteraemia of 
$2836 per case. Tambyah et al11 reported that the mean 
incremental hospitalisation cost attributable to nosoco-
mial catheter-associated UTI was $589. However, studies 
that focused on UTI infections treated in primary care 
have reported a mean cost between €709 and €23610 per 
episode.
This is the first study to examine costs of hospitalised 
patients due to cUTI from a multinational point of view. 
Moreover, it is focused on countries with a high prevalence 
of MDR bacteria where cUTI impose a significant burden. 
In addition, the study estimated the mean cost per case 
from a bottom-up perspective, which provided a high level 
of granularity and the basis for the assessment of sources 
of variation and drivers of healthcare costs. However, the 
study also has a number of limitations. The design of the 
study did not include a control group to assess the extra 
length of stay and excess costs of patients who are admitted 
to hospital due to a different condition and develop UTI 
during their hospitalisation. Therefore, we focused in this 
paper on the analysis of patients who are admitted because 
of a cUTI. This is to avoid the overestimation that would 
result among cases admitted for other reasons for whom 
we cannot isolate the incremental costs that are due to 
cUTI only. A second limitation of the analysis is that, as 
discussed in the Methods section, country-specific unit cost 
data were not appropriate for most countries, and there-
fore we applied the same set of unit costs, as estimated in 
one country, Spain, to the rest of the countries. While this 
approach allowed us to explore variations in healthcare costs 
that are due to differences in the management of patients 
with cUTI across countries rather than due to differences 
in the unit costs of services, it limits the validity of the coun-
try-specific estimates. To further explore the heterogeneity 
of country-specific estimates, we planned to use the tool 
developed by WHO-CHOICE health service delivery costs,22 
which provides information on the unit costs of bed-days 
and outpatient visits across 191 countries. The information 
from this dataset indicates that variations in cost estimates 
across countries would be enhanced if country-specific unit 
costs were used. The countries with the highest unit costs 
according to this tool, that is, Spain, Italy and Greece, are 
among the countries with higher episode costs based on 
healthcare utilisation in our analysis, while the country with 
the lowest unit cost, Bulgaria, has an estimated episode cost 
among the lowest in this study. Unfortunately, unit costs 
values from this tool are only available for inpatient and 
outpatient visits, and for 2007–2008, and therefore they 
could not be used to construct country-specific estimates. 
In addition, we acknowledge that the theoretical proper 
unit cost for a resource is its opportunity cost (the value of 
the foregone benefits because the resources are not avail-
able for their next best alternative use). We take, as most 
previous studies, a pragmatic approach of using market 
prices and accounting costs. However, it is worth noting that, 
especially for inpatient day cost, these values might overesti-
mate their opportunity costs. This is because most hospital 
costs are fixed and cannot be recouped even if the admis-
sion is avoided.26 We also acknowledge that the number of 
observations included in the study for some countries is low, 
ranging from 31 to 170, which might restrict the generalis-
ability of country-specific findings. The explanatory power 
of our models was also found to be low, which might suggest 
that there are other factors not captured by the observed 
variables included in our models that explain variation in 
healthcare costs, such as hospital policy on LOS. Finally, the 
perspective of the analysis was that of the hospital provider; 
however, if a societal perspective had been considered wider 
costs related to cUTI should had been taken into account, 
such as patients’ costs and productivity losses due to illness, 
as well as cost incurred by primary care settings, including 
these costs would increase the costs of cUTI.
In conclusion, this study showed the costs of patients 
hospitalised due to cUTI are substantial but identified wide 
differences between countries, especially due to differences 
in length of stay in the hospital. These findings suggest that a 
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better knowledge of the reasons for longer length of stays in 
some countries could facilitate a better standardised quality 
of care for patients with cUTI and to allow a more efficient 
allocation of healthcare resources. The factors associated 
with higher cUTI-related healthcare costs identified by this 
study also shed light onto some implications for policy and 
planning. Prompting preventive measures to minimise cost 
of hospitalisation might be aimed at increasing the popu-
lation’s knowledge of symptoms and signs of infection, in 
order to encourage patients to attend primary care facilities 
earlier, especially those with comorbidities or indwelling 
urinary catheters, and thus to avoid the development of 
severe forms of illness after the onset of symptoms and 
avoid the need for urgent admissions.
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